Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression

Jing Liao, Yan Luan, Zhenhua Ren, Xiaojuan Liu, Diyuan Xue, Hairong Xu, Zhichen Sun, Kaiting Yang, Hua Peng, Yang Xin Fu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Anti-hCD20 is a therapeutic mAb that is clinically used to treat B-cell lymphoma. Some lymphomas are resistant to anti-hCD20; others relapse after treatment with anti-hCD20. Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)- associated systemic toxicity in the host. Control of tumors by a fusion of anti-CD20 and IFNα (anti-CD20-IFNα) depended on existing tumor-infiltrating CD8+ T cells. Although lymphomas were resistant to IFN-directed killing, IFN-exposed tumor cells became the dominant antigen-presenting cells (APC) for the reactivation of tumor-infiltrating CD8+ T cells that then controlled those lymphomas. Anti-CD20-IFNα also abolished checkpoint blockade resistance in advanced B-cell lymphoma. Our findings indicate that anti-CD20-IFNα eradicates B-cell lymphoma by employing tumor cells as APCs to reactivate tumor-infiltrating CD8+ T cells and synergizing with anti-PD-L1 treatment. Cancer Immunol Res; 5(7); 560-70.

Original languageEnglish (US)
Pages (from-to)560-570
Number of pages11
JournalCancer immunology research
Volume5
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Antigen-Presenting Cells
Interferons
Lymphoma
B-Cell Lymphoma
Neoplasms
T-Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression. / Liao, Jing; Luan, Yan; Ren, Zhenhua; Liu, Xiaojuan; Xue, Diyuan; Xu, Hairong; Sun, Zhichen; Yang, Kaiting; Peng, Hua; Fu, Yang Xin.

In: Cancer immunology research, Vol. 5, No. 7, 01.07.2017, p. 560-570.

Research output: Contribution to journalArticle

Liao, Jing ; Luan, Yan ; Ren, Zhenhua ; Liu, Xiaojuan ; Xue, Diyuan ; Xu, Hairong ; Sun, Zhichen ; Yang, Kaiting ; Peng, Hua ; Fu, Yang Xin. / Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression. In: Cancer immunology research. 2017 ; Vol. 5, No. 7. pp. 560-570.
@article{0997e9daeada4ca28c929c7cea24d622,
title = "Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression",
abstract = "Anti-hCD20 is a therapeutic mAb that is clinically used to treat B-cell lymphoma. Some lymphomas are resistant to anti-hCD20; others relapse after treatment with anti-hCD20. Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)- associated systemic toxicity in the host. Control of tumors by a fusion of anti-CD20 and IFNα (anti-CD20-IFNα) depended on existing tumor-infiltrating CD8+ T cells. Although lymphomas were resistant to IFN-directed killing, IFN-exposed tumor cells became the dominant antigen-presenting cells (APC) for the reactivation of tumor-infiltrating CD8+ T cells that then controlled those lymphomas. Anti-CD20-IFNα also abolished checkpoint blockade resistance in advanced B-cell lymphoma. Our findings indicate that anti-CD20-IFNα eradicates B-cell lymphoma by employing tumor cells as APCs to reactivate tumor-infiltrating CD8+ T cells and synergizing with anti-PD-L1 treatment. Cancer Immunol Res; 5(7); 560-70.",
author = "Jing Liao and Yan Luan and Zhenhua Ren and Xiaojuan Liu and Diyuan Xue and Hairong Xu and Zhichen Sun and Kaiting Yang and Hua Peng and Fu, {Yang Xin}",
year = "2017",
month = "7",
day = "1",
doi = "10.1158/2326-6066.CIR-16-0221",
language = "English (US)",
volume = "5",
pages = "560--570",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Converting lymphoma cells into potent antigen-presenting cells for interferon-induced tumor regression

AU - Liao, Jing

AU - Luan, Yan

AU - Ren, Zhenhua

AU - Liu, Xiaojuan

AU - Xue, Diyuan

AU - Xu, Hairong

AU - Sun, Zhichen

AU - Yang, Kaiting

AU - Peng, Hua

AU - Fu, Yang Xin

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Anti-hCD20 is a therapeutic mAb that is clinically used to treat B-cell lymphoma. Some lymphomas are resistant to anti-hCD20; others relapse after treatment with anti-hCD20. Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)- associated systemic toxicity in the host. Control of tumors by a fusion of anti-CD20 and IFNα (anti-CD20-IFNα) depended on existing tumor-infiltrating CD8+ T cells. Although lymphomas were resistant to IFN-directed killing, IFN-exposed tumor cells became the dominant antigen-presenting cells (APC) for the reactivation of tumor-infiltrating CD8+ T cells that then controlled those lymphomas. Anti-CD20-IFNα also abolished checkpoint blockade resistance in advanced B-cell lymphoma. Our findings indicate that anti-CD20-IFNα eradicates B-cell lymphoma by employing tumor cells as APCs to reactivate tumor-infiltrating CD8+ T cells and synergizing with anti-PD-L1 treatment. Cancer Immunol Res; 5(7); 560-70.

AB - Anti-hCD20 is a therapeutic mAb that is clinically used to treat B-cell lymphoma. Some lymphomas are resistant to anti-hCD20; others relapse after treatment with anti-hCD20. Using a syngeneic immunocompetent mouse model, we observed that targeting lymphoma with interferon-α (IFNα) abolished resistance of B-cell lymphoma to anti-CD20 while limiting interferon (IFN)- associated systemic toxicity in the host. Control of tumors by a fusion of anti-CD20 and IFNα (anti-CD20-IFNα) depended on existing tumor-infiltrating CD8+ T cells. Although lymphomas were resistant to IFN-directed killing, IFN-exposed tumor cells became the dominant antigen-presenting cells (APC) for the reactivation of tumor-infiltrating CD8+ T cells that then controlled those lymphomas. Anti-CD20-IFNα also abolished checkpoint blockade resistance in advanced B-cell lymphoma. Our findings indicate that anti-CD20-IFNα eradicates B-cell lymphoma by employing tumor cells as APCs to reactivate tumor-infiltrating CD8+ T cells and synergizing with anti-PD-L1 treatment. Cancer Immunol Res; 5(7); 560-70.

UR - http://www.scopus.com/inward/record.url?scp=85021927694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021927694&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-16-0221

DO - 10.1158/2326-6066.CIR-16-0221

M3 - Article

C2 - 28533311

AN - SCOPUS:85021927694

VL - 5

SP - 560

EP - 570

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 7

ER -